Sep 12, 2022 / 05:40PM GMT
Michael Eric Ulz - Morgan Stanley, Research Division - Equity Analyst
All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, the biotech analyst here. And it's my pleasure to introduce Fred Schwarzer, CEO of IGM Biosciences. Format for today is a fireside chat. But just before we get started, I need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research website at www.morganstanley.com\researchdisclosures.
(Operator Instructions)
Questions and Answers:
Michael Eric Ulz - Morgan Stanley, Research Division - Equity AnalystAnd with that, we can just hop straight into Q&A and maybe Thanks, Fred, for joining us here. And maybe if there's people who aren't familiar with IGM Biosciences, -- maybe you can just talk about some of the key differences between an IGM antibody and an IGG antibody and maybe why people have seemed to focus on IGG?
Fred M. Schwarzer - IGM Biosciences, Inc. - CEO,
Trustpilot
